From New York Post · · 50s
GLP-1 Injections Recalled Nationwide
FDA recalls Apothecary Pharma's compounded GLP-1 injections due to contamination risks.
In brief
FDA recalls Apothecary Pharma's compounded GLP-1 injections due to contamination risks. The FDA has recalled 22 vials of Apothecary Pharma's compounded tirzepatide for potential contamination, affecting users of the drug despite brand-name versions being safe. Originally reported by New York Post.
FDA Recall Announcement
The FDA has recalled 22 vials of Apothecary Pharma's compounded tirzepatide for potential contamination risks.
Recalled Vial Details
Recalled vials are labeled 18 mg/mL in a 4 mL multidose vial with lot numbers AP-202622 to AP-202644.
Previous FDA Warning
The FDA issued a warning letter last December after finding serious deficiencies in Apothecary Pharma's sterile production practices.
Contamination Risks
Using contaminated compounded GLP-1s could cause temporary health issues, though severe consequences are unlikely.
Recall Impact
Even if you didn't buy directly from Apothecary Pharma, your medication could still be affected through telehealth providers.
What to remember
The FDA has recalled 22 vials of Apothecary Pharma's compounded tirzepatide for potential contamination, affecting users of the drug despite brand-name versions being safe.
